Inflammatory Bowel Diseases

AUG 19, 2026 · PHASE 2 TRIAL

Trial of Mirtazapine for Depression in IBD

ClinicalTrials.gov

A Phase 2 feasibility trial with no results reported; designed to assess recruitment and trial conduct in a specific population, not to evaluate efficacy.

AUG 15, 2026 · JOURNAL ARTICLE

Synthetic microbial communities: emerging live biotherapeutics for targeted gut microbiome modulation.

Gut Microbes

A narrative review synthesizing the state of knowledge on synthetic microbial communities as emerging biotherapeutics, establishing boundaries, mechanisms, and translational challenges without reporting primary experimental results.

AUG 13, 2026 · JOURNAL ARTICLE

Bifidobacterium and the gut-immune axis: Mechanistic insights and therapeutic potential.

Microbiological Research

This narrative review synthesizes mechanistic and preclinical evidence on Bifidobacterium immunomodulation but explicitly states outcomes remain heterogeneous and lacks definitive clinical trials, positioning it as an exploratory synthesis raising questions rather than settling them.

JUL 16, 2026 · JOURNAL ARTICLE

From signals to systems: the epigenetic-microbiome-mitochondrial axis in IBD pathogenesis.

Gut Microbes

This is a narrative review synthesizing mechanistic concepts and existing literature about epigenetic-microbiome-mitochondrial interactions in IBD pathogenesis, raising integrative questions rather than reporting original experimental or clinical evidence.

JUN 15, 2026 · JOURNAL ARTICLE

Crosstalk between circRNAs and the classic signaling pathways in IBD.

Rna Biology

This is a narrative review synthesizing early-stage research on circRNAs in IBD pathogenesis; no primary experimental or clinical data are presented, and evidence remains exploratory with limited mechanistic validation.